Physician profile
Kevin Nethers
NPI 1932631009
$6,816.31
in general payments reported to CMS, 2019-2025
24 companies · $2,446 in 2025
The $2,446 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $406 · 2021: $600 · 2022: $828 · 2023: $1,022 · 2024: $652 · 2025: $2,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,879 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,878.97 |
| Education | $240.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,343.99 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $479.72 | 2019-2025 | Dupixent |
| Incyte Corporation | $415.67 | 2023-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $372.43 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $342.65 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $297.81 | 2022-2025 | |
| Janssen Biotech, INC. | $291.36 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $275.99 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Genentech USA, INC. | $258.55 | 2019-2021 | |
| Leo Pharma INC. | $243.13 | 2022-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $204.98 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $188.16 | 2019-2021 | |
| Dermavant Sciences, INC. | $155.33 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $149.91 | 2021-2025 | |
| Pfizer INC. | $149.72 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $149.03 | 2025 | |
| Amgen INC. | $145.65 | 2023-2025 | Otezla, Enbrel, Otezla |
| Argenx US, INC. | $108.02 | 2023 | Vyvgart |
| Ucb, INC. | $94.79 | 2021-2025 | Bimzelx |
| Organogenesis INC. | $70.65 | 2025 | Apligraf |
| Mayne Pharma Commercial LLC | $32.55 | 2020 | |
| Celgene Corporation | $21.55 | 2019 | |
| Almirall LLC | $19.32 | 2022 | |
| Organon LLC | $5.35 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Nethers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.